International Assets Investment Management LLC Invests $3.75 Million in Henry Schein, Inc. (NASDAQ:HSIC)

International Assets Investment Management LLC bought a new position in shares of Henry Schein, Inc. (NASDAQ:HSIC) in the fourth quarter, HoldingsChannel reports. The firm bought 49,590 shares of the company’s stock, valued at approximately $3,754,000.

A number of other institutional investors also recently modified their holdings of HSIC. Baystate Wealth Management LLC boosted its holdings in shares of Henry Schein by 2,500.0% during the third quarter. Baystate Wealth Management LLC now owns 520 shares of the company’s stock worth $39,000 after purchasing an additional 500 shares during the period. McGlone Suttner Wealth Management Inc. bought a new position in Henry Schein in the fourth quarter worth about $39,000. Neo Ivy Capital Management bought a new position in Henry Schein in the third quarter worth about $46,000. Covestor Ltd raised its stake in Henry Schein by 88.4% in the first quarter. Covestor Ltd now owns 861 shares of the company’s stock worth $75,000 after buying an additional 404 shares in the last quarter. Finally, RVW Wealth LLC bought a new position in Henry Schein in the third quarter worth about $104,000. 96.62% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Henry Schein

In related news, CEO Bradford C. Connett sold 6,430 shares of the firm’s stock in a transaction that occurred on Wednesday, March 20th. The shares were sold at an average price of $74.28, for a total transaction of $477,620.40. Following the completion of the sale, the chief executive officer now owns 73,108 shares of the company’s stock, valued at $5,430,462.24. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, Vice Chairman James P. Breslawski sold 2,907 shares of the firm’s stock in a transaction that occurred on Monday, March 18th. The shares were sold at an average price of $74.37, for a total transaction of $216,193.59. Following the completion of the sale, the insider now owns 209,562 shares of the company’s stock, valued at $15,585,125.94. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Bradford C. Connett sold 6,430 shares of the firm’s stock in a transaction that occurred on Wednesday, March 20th. The shares were sold at an average price of $74.28, for a total transaction of $477,620.40. Following the sale, the chief executive officer now directly owns 73,108 shares of the company’s stock, valued at approximately $5,430,462.24. The disclosure for this sale can be found here. 1.14% of the stock is owned by insiders.

Henry Schein Price Performance

Shares of NASDAQ HSIC opened at $71.22 on Wednesday. Henry Schein, Inc. has a fifty-two week low of $60.01 and a fifty-two week high of $85.39. The company has a 50 day simple moving average of $74.63 and a two-hundred day simple moving average of $72.52. The company has a market capitalization of $9.15 billion, a price-to-earnings ratio of 22.61, a P/E/G ratio of 1.76 and a beta of 0.87. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.00 and a current ratio of 1.67.

Henry Schein (NASDAQ:HSIC) last announced its quarterly earnings results on Tuesday, February 27th. The company reported $0.66 earnings per share for the quarter, missing the consensus estimate of $0.70 by ($0.04). The firm had revenue of $3.02 billion for the quarter, compared to the consensus estimate of $3 billion. Henry Schein had a net margin of 3.37% and a return on equity of 14.03%. Henry Schein’s revenue was down 10.5% on a year-over-year basis. During the same period last year, the business earned $1.21 EPS. Analysts expect that Henry Schein, Inc. will post 5.07 EPS for the current fiscal year.

Analyst Ratings Changes

HSIC has been the subject of a number of research reports. Barrington Research increased their price target on shares of Henry Schein from $82.00 to $90.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 28th. Jefferies Financial Group increased their price target on shares of Henry Schein from $74.00 to $81.00 and gave the stock a “hold” rating in a research note on Wednesday, March 6th. Leerink Partnrs reissued a “market perform” rating on shares of Henry Schein in a research note on Monday, February 26th. Piper Sandler increased their price target on shares of Henry Schein from $78.00 to $86.00 and gave the stock an “overweight” rating in a research note on Monday, February 26th. Finally, JPMorgan Chase & Co. increased their price target on shares of Henry Schein from $82.00 to $88.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 6th. One analyst has rated the stock with a sell rating, six have assigned a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, Henry Schein has an average rating of “Hold” and a consensus target price of $81.09.

Henry Schein Profile

Henry Schein, Inc provides health care products and services to dental practitioners and laboratories, physician practices, ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.